MLYS: Mineralys Therapeutics Inc

15.05 USD 0.99 (7.04%)

セクター: ヘルスケアベース: US Dollar 利益通貨: US Dollar

MLYSの今日の為替レートは、7.04%変化しました。日中、通貨は1あたり13.97の安値と15.13の高値で取引されました。

Mineralys Therapeutics Incダイナミクスに従います。リアルタイムの相場は、市場の変化に迅速に対応するのに役立ちます。異なる時間枠に切り替えることで、為替レートの傾向とダイナミクスを分、時間、日、週、月単位で監視できます。この情報を使用して、市場の変化を予測し、十分な情報に基づいて取引を決定してください。

全画面チャート

MLYS News

Zacks 16:00 Mineralys Therapeutics, Inc. (MLYS) Upgraded to Buy: Here's Why
Zacks 13:55 Does Mineralys Therapeutics, Inc. (MLYS) Have the Potential to Rally 154.21% as Wall Street Analysts Expect?
Investing 21:08 Mineralys Therapeutics CEO Congleton sells $230k in shares
Investing 21:06 Mineralys Therapeutics CFO Adam Levy sells $155k in stock
TipRanks 10:30 3 Best Stocks to Buy Now, 7/15/2025, According to Top Analysts - TipRanks.com
Investing 13:13 Jefferies maintains Hold rating on Mineralys stock amid AstraZeneca data
Investing 15:25 Mineralys reports positive phase 3 results for hypertension drug
Investing 11:31 Mineralys stock holds Buy rating at H.C. Wainwright after CKD trial
Benzinga 13:57 Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps - Mineralys Therapeutics (NASDAQ:MLYS)
Investing 12:35 Mineralys Therapeutics stock jumps after positive kidney disease trial data
Investing 11:05 Mineralys reports positive phase 2 data for lorundrostat in CKD
Seeking Alpha 14:10 PGIM Jennison Health Sciences Fund Q1 2025 Commentary (PHLAX)
Benzinga 12:35 This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Core Natural Resources (NYSE:CNR), Coinbase Global (NASDAQ:COIN)
Investing 21:01 Jefferies initiates Mineralys Therapeutics stock with hold rating
Seeking Alpha 03:36 Akebia Therapeutics (AKBA): Stock At Fair Value Amid Robust Drug Adoption Into 2026
Seeking Alpha 15:51 Mineralys Therapeutics: Merits A Small 'Speculative' Holding (NASDAQ:MLYS)
Investing 10:13 Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension
Investing 12:05 Mineralys to present lorundrostat trial data at ESH 2025
Investing 00:04 Mineralys at BofA Securities 2025: Lorundrostat’s Hypertension Promise
TipRanks 09:35 3 Best Stocks to Buy Now, 4/1/2025, According to Top Analysts - TipRanks.com
TipRanks 09:53 3 Best Stocks to Buy Now, 3/31/2025, According to Top Analysts - TipRanks.com
Investing 18:40 Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual
Benzinga 12:36 Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Lazard (NYSE:LAZ), Amylyx Pharmaceuticals (NASDAQ:AMLX)
Seeking Alpha 22:25 Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts (NASDAQ:MLYS)

1日のレンジ

13.97 15.13

1年のレンジ

8.24 18.99

以前の終値: 13.88
始値: 14.06

買値: 15.05
買値: 15.35

安値: 13.97
高値: 15.13

出来高: 662

1日の変化: 7.04%
1ヶ月の変化: 11.65%

6ヶ月の変化: 46.12%
1年の変化: 20.50%

30 7月, 水曜日